Semaglutide Oral (Pills and Capsules): What Studies Show
Which studies gave Semaglutide as a oral form, what they measured, and what is approved. No product recommendations.
- Route
- oral
- FDA-approved product for this route
- None
- Route studies (human / animal)
- 3 / 0
- in our evidence file (PubMed search, 2 Oct 2026)
Studies that gave Semaglutide oral
Each row is a study whose stated route matches. Animal and cell results are labelled and are not human results.
| Study | Design | n | Dose | First outcome |
|---|---|---|---|---|
| Lancet 2026, PMID 41865758 | Human RCT | 3,808 | 14 mg (flexible dose) | Clinical Dementia Rating-Sum of Boxes: Oral semaglutide did not slow clinical progression in early Alzheimer disease; both trials were discontinued for negative outcome. |
| The New England journal of medicine 2025, PMID 40934115 | Human RCT | 307 | 25 mg | Body weight change (oral): Oral semaglutide changed body weight by -13.6% vs -2.2% with placebo at week 64. |
| The New England journal of medicine 2019, PMID 31185157 | Human RCT | 3,183 | Not stated | Major adverse cardiovascular events: Major events occurred in 3.8% on oral semaglutide vs 4.8% on placebo (hazard ratio 0.79, 95% CI 0.57 to 1.11), establishing noninferiority. |
For the injected form, see Semaglutide how to inject and Semaglutide half-life.
Trials that tested semaglutide taken by mouth
A once-daily oral dose was tested against placebo for 64 weeks in adults with overweight or obesity and no diabetes, with weight falling 13.6% on oral semaglutide against 2.2% on placebo.[2]
A cardiovascular safety trial of once-daily oral semaglutide in people with type 2 diabetes found major cardiovascular events in 3.8% on oral semaglutide and 4.8% on placebo, a result designed to show non-inferiority rather than benefit.[3]
Two phase 3 trials of oral semaglutide in early Alzheimer's disease concluded it was not efficacious in slowing clinical progression.[1]
How much semaglutide a tablet absorbs compared with an injection
The Wegovy label reports 89% absolute bioavailability after a subcutaneous injection.[4]
For the tablet form the same label estimates absolute bioavailability at roughly 1% to 2%.[4]
The Rybelsus tablets label gives 0.4% to 1% bioavailability for its 3 mg, 7 mg and 14 mg strengths.[5]
In the label's fasting study, absorption was higher after a longer wait following the dose.[5]
What the tablet labels say about taking them
The Rybelsus and Ozempic tablets label directs one tablet daily on an empty stomach with up to 4 ounces of plain water.[5]
That label says the tablets and the injection are not interchangeable milligram for milligram.[5]
The Wegovy tablet instructions say to swallow whole and wait 30 minutes before eating or drinking.[4]
Safety findings from the oral trials
In the oral weight trial, gastrointestinal adverse events were reported in 74.0% on oral semaglutide and 42.2% on placebo.[2]
In the Alzheimer's trials, treatment-emergent adverse events were reported by 91.2% of participants on oral semaglutide and 84.8% on placebo.[1]
The Wegovy label advises against breastfeeding during treatment with the tablets because of the SNAC ingredient.[4]
Common questions
Is there an FDA-approved oral form of Semaglutide?
We found no FDA-approved oral product for Semaglutide in our evidence file. Products sold as oral forms are not checked by the FDA.
Have studies given Semaglutide as a oral form?
3 studies in our evidence file gave Semaglutide by a oral route: 3 in people and 0 in animals.
Is there a semaglutide pill?
Yes: the Rybelsus and Ozempic tablets label describes once-daily tablets taken on an empty stomach.[5]
Do semaglutide pills work as well as injections?
No trial quoted here compares the two forms head to head, so this page does not rank them; the label does say the tablets are not substitutable on a mg-to-mg basis.[5]
More on Semaglutide
Sources
- 1Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 2Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 3Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2019PMID 31185157Accessed 2 Oct 2026
- 4WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 5RYBELSUS and OZEMPIC tablets prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.